Gallium‐68‐prostate‐specific membrane antigen (<sup>68</sup>Ga<scp>‐PSMA)</scp> positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer

Leeuwen, Pim J. van; Donswijk, Maarten L.; Nandurkar, Rohan; Stricker, Phillip D.; Ho, Bao; Heijmink, Stijn W. T. P. J.; Wit, Esther; Tillier, Corinne; Muilenkom, Erik van; Nguyen, Quoc; Poel, Henk G. van der; Emmett, Louise

doi:10.1111/bju.14506

Cited by 64 publications

(68 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eleven studies were included in this review that presented data on the sensitivity and specificity of 68 Ga-PSMA PET for detection of pelvic lymph node metastases in men with newly diagnosed PCa (Table 1, Fig. 1) [8, [10][11][12][13][14][15][16][17][18][19]. Two prospective studies, including a total of 63 patients, showed a per-patient sensitivity (range) and specificity (range) of 64-100% and 90-95%, respectively.…”

Section: Diagnostic Performance Of 68 Ga-psma Pet For Pelvic Lymph Nomentioning

confidence: 99%

See 1 more Smart Citation

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Luiting¹,

Leeuwen

Busstra³

et al. 2019

BJU International

Self Cite

View full text Add to dashboard Cite

ObjectivesTo review the literature to determine the sensitivity and specificity of gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) positron-emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of 68 Ga-PSMA PET in patients with BCR after radical prostatectomy (RP). Materials and MethodsWe performed a comprehensive literature search. Search terms used in MEDLINE, EMBASE and Science Direct were '(PSMA, 68 Ga-PSMA, 68 Gallium-PSMA, Ga-68-PSMA or prostate-specific membrane antigen)' and '(histology, lymph node, staging, sensitivity, specificity, positive predictive value, recurrence, recurrent or detection)'. Relevant abstracts were reviewed and full-text articles obtained where possible. References to and from obtained articles were searched to identify further relevant articles. ResultsNine retrospective and two prospective studies described the sensitivity and specificity of 68 Ga-PSMA PET for detecting pelvic lymph node metastases before initial treatment, which ranged from 33.3% to 100% and 80% to 100%, respectively. In eight retrospective studies, the positive predictive value of 68 Ga-PSMA PET in patients with BCR before salvage lymph node dissection ranged from 70% to 100%. The detection rate of 68 Ga-PSMA PET in patients with BCR after RP in the PSA subgroups <0.2 ng/mL, 0.2-0.49 ng/mL and 0.5 to <1.0 ng/ mL ranged from 11.3% to 50.0%, 20.0% to 72.7% and 25.0% to 87.5%, respectively. ConclusionThe review results showed that 68 Ga-PSMA PET had a high specificity for the detection of pelvic lymph node metastases in primary PCa. Furthermore, 68 Ga-PSMA PET had a very high positive predictive value in detecting lymph node metastases in patients with BCR. By contrast, sensitivity was only moderate; therefore, based on the currently available literature, 68 Ga-PSMA PET cannot yet replace pelvic lymph node dissection to exclude lymph node metastases. In the salvage phase, 68 Ga-PSMA PET had both a high detection rate and impact on radiotherapy planning in early BCR after RP. Keywords 68Ga-PSMA PET/CT, pelvic lymph node dissection, detection rate, pelvic lymph node metastases, #ProstateCancer, #PCSM Use of 68Ga-PSMA PET/CT after RP: review IQR, interquartile range; LNM, lymph node metastases. *Gallium-68 prostate-specific membrane antigen positron-emission tomography ( 68 Ga-PSMA PET)/MRI was used instead of 68 Ga-PSMA PET/CT. 208

show abstract

Section: Diagnostic Performance Of 68 Ga-psma Pet For Pelvic Lymph Nomentioning

confidence: 99%

“…Nine retrospective studies, including 696 patients, showed a per-patient sensitivity and specificity of 33.3-100% and 80-100%. The per-node sensitivity and specificity was 24.4-96.1% and 98.6-100%, respectively [8, [10][11][12][13][14]16,17,20].…”

Section: Diagnostic Performance Of 68 Ga-psma Pet For Pelvic Lymph Nomentioning

confidence: 99%

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Luiting¹,

Leeuwen

Busstra³

et al. 2019

BJU International

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the present study by Leeuwen et al. , 140 patients with newly diagnosed intermediate‐ or high‐ risk prostate cancer underwent 68 Ga‐PSMA‐11 PET/CT before radical prostatectomy with extended pelvic lymph node dissection. Surgical pathology served as the reference standard to which findings on 68 Ga‐PSMA‐11 PET/CT were compared.…”

mentioning

confidence: 74%

“…In this edition of the BJUI , Leeuwen et al. report on the utility of molecular imaging with 68 Ga‐PSMA‐11 positron emission tomography (PET)/CT in the preoperative staging of men with prostate cancer. To date, the greatest clinical utility of PSMA‐targeted PET has been in the management of men with biochemically recurrent prostate cancer .…”

mentioning

confidence: 99%

Preoperative PSMA‐targeted PET imaging: more than just a tool for prostate cancer staging?

2019

View full text Add to dashboard Cite

“…PSMA PET has led to improvement in estimating the burden of disease in primary and recurrent prostate cancer with high sensitivity and specificity . Although early data suggests that PSMA PET may be useful for predicting disease response, it is unclear how to interpret the intensity of PSMA expression in relation to Gleason score, tumor biology, tumor microenvironment, and androgen dependency. In a case series of men with metastatic prostate cancer treated with frontline and salvage chemotherapy, concordance between PSA and PSMA PET response was reported .…”

Section: Imaging Approaches For Identifying Aggressive Prostate Cancementioning

confidence: 99%

Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira

Den²,

Carlo³

et al. 2018

The Prostate

View full text Add to dashboard Cite

Introduction The 2018 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, “Tumor Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24, 2018. Methods The CHPCA Meeting is a unique, discussion‐oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. Results The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. Discussion This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

show abstract

Gallium‐68‐prostate‐specific membrane antigen (⁶⁸Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer

Abstract: 68Ga-PSMA-11 PET/CT is highly predictive for BCP to RP, and should play an important role informing men with intermediate or high-risk PC. This article is protected by copyright. All rights reserved.

Cited by 64 publications

References 15 publications

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Preoperative PSMA‐targeted PET imaging: more than just a tool for prostate cancer staging?

Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting

Contact Info

Product

Resources

About

Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer

Abstract: 68Ga-PSMA-11 PET/CT is highly predictive for BCP to RP, and should play an important role informing men with intermediate or high-risk PC. This article is protected by copyright. All rights reserved.

Cited by 64 publications

References 15 publications

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Preoperative PSMA‐targeted PET imaging: more than just a tool for prostate cancer staging?

Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting

Contact Info

Product

Resources

About

Gallium‐68‐prostate‐specific membrane antigen (⁶⁸Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer